[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-001", "question": "A 4-year-old boy presents with recurrent bacterial infections since infancy, including pneumonia and otitis media. Laboratory evaluation reveals absent CD19+ B cells, normal T cell numbers with preserved proliferation to mitogens, and undetectable serum immunoglobulins. Genetic testing identifies a mutation in a cytoplasmic tyrosine kinase essential for B cell development. His 2-year-old brother is asymptomatic but has the same mutation. Which of the following best explains the brother's lack of clinical manifestations?", "options": ["Residual maternal IgG providing passive immunity", "Somatic mosaicism with partial gene function restoration", "Compensatory upregulation of alternative signaling pathways", "X-chromosome inactivation favoring the wild-type allele", "Presence of a hypomorphic rather than null mutation"], "answer": "A", "answer_index": 0, "explanation": "This case describes X-linked agammaglobulinemia (XLA) due to BTK mutation. At age 2, the asymptomatic brother may still have residual transplacentally acquired maternal IgG, which typically wanes by 6-9 months but can persist longer in some cases, providing temporary protection. X-chromosome inactivation is irrelevant as this is an X-linked recessive condition affecting males who have only one X chromosome. Somatic mosaicism and hypomorphic mutations would show some B cell development, which is absent here.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the provided key is not the best answer. The stem describes a 2-year-old boy with the same BTK mutation as his 4-year-old brother who has XLA. Key discriminating findings: both brothers have identical mutations causing absent CD19+ B cells and undetectable immunoglobulins; the 4-year-old is symptomatic while the 2-year-old is asymptomatic. The keyed answer (A) is medically implausible: maternal IgG typically wanes by 6-9 months, and by age 2 years would be completely depleted, providing no protection. A child with absent B cells and undetectable immunoglobulins at age 2 would have experienced infections by this age. The best answer is E (hypomorphic mutation): the stem states genetic testing found 'a mutation' but does not specify both brothers have identical phenotypes - the asymptomatic brother could have a different, less severe (hypomorphic) allele allowing some residual B cell function. Alternatively, B (somatic mosaicism) could explain preserved function in some cell lineages. The item is underspecified regarding whether both brothers have identical mutations affecting function identically, but even accepting that premise, option A is temporally implausible at age 2. Minimal fix: specify the 2-year-old brother is 6-8 months old, making maternal IgG persistence plausible.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the provided key is not the best answer. The stem describes a 2-year-old boy with the same BTK mutation as his 4-year-old brother who has XLA. Key discriminating findings: both brothers have identical mutations causing absent CD19+ B cells and undetectable immunoglobulins; the 4-year-old is symptomatic while the 2-year-old is asymptomatic. The keyed answer (A) is medically implausible: maternal IgG typically wanes by 6-9 months, and by age 2 years would be completely depleted, providing no protection. A child with absent B cells and undetectable immunoglobulins at age 2 would have experienced infections by this age. The best answer is E (hypomorphic mutation): the stem states genetic testing found 'a mutation' but does not specify both brothers have identical phenotypes - the asymptomatic brother could have a different, less severe (hypomorphic) allele allowing some residual B cell function. Alternatively, B (somatic mosaicism) could explain preserved function in some cell lineages. The item is underspecified regarding whether both brothers have identical mutations affecting function identically, but even accepting that premise, option A is temporally implausible at age 2. Minimal fix: specify the 2-year-old brother is 6-8 months old, making maternal IgG persistence plausible.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-002", "question": "A 58-year-old woman with metastatic melanoma receiving combination ipilimumab and nivolumab develops acute onset confusion, fever to 39.2°C, and neck stiffness on day 21 of treatment. CSF analysis shows 180 WBC/μL (92% lymphocytes), protein 156 mg/dL, glucose 52 mg/dL (serum 98 mg/dL), and negative Gram stain. MRI brain shows leptomeningeal enhancement. CSF cytology and flow cytometry are negative for malignant cells. Which additional CSF finding would most strongly support the diagnosis of immune checkpoint inhibitor-induced aseptic meningitis over infectious or neoplastic etiologies?", "options": ["Elevated CSF adenosine deaminase level", "Presence of oligoclonal bands with matched serum bands", "Markedly elevated CSF IL-17 levels", "CD4+/CD8+ T cell ratio greater than 4:1 with activated phenotype", "Elevated CSF beta-2 microglobulin"], "answer": "D", "answer_index": 3, "explanation": "Immune checkpoint inhibitor-induced aseptic meningitis characteristically shows a CD4+ predominant lymphocytic pleocytosis with activated T cell phenotype (expressing HLA-DR, CD69), reflecting the mechanism of enhanced T cell activation. Elevated ADA suggests tuberculosis; oligoclonal bands suggest MS or infectious processes; elevated IL-17 is nonspecific; beta-2 microglobulin elevation occurs in lymphomatous meningitis. The CD4+/CD8+ ratio with activation markers specifically reflects the immunologic mechanism of checkpoint inhibitor toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem presents a 58-year-old woman on ipilimumab/nivolumab with aseptic meningitis (lymphocytic CSF, negative Gram stain/cytology). The question asks which CSF finding most strongly supports checkpoint inhibitor-induced meningitis over infectious/neoplastic causes. Key issue: The keyed answer (D: CD4+/CD8+ ratio >4:1 with activated phenotype) lacks robust published evidence as a specific diagnostic marker for checkpoint inhibitor meningitis. While checkpoint inhibitors enhance T-cell activation, a CD4+/CD8+ ratio >4:1 is not established as pathognomonic and could occur in various inflammatory conditions. Option C (markedly elevated IL-17) is equally plausible given that IL-17 is implicated in immune-related adverse events from checkpoint inhibitors and Th17 responses. The stem does not provide sufficient discriminating information to definitively favor D over C based on established literature. Both represent immunologic activation patterns that could theoretically support checkpoint inhibitor toxicity, but neither is validated as a gold-standard diagnostic marker. The item assumes knowledge of a specific biomarker profile that is not widely established in standard references. Minimal fix: Revise the question to ask about general immunologic patterns rather than specific ratios, or provide stem clues that better discriminate between inflammatory cytokine profiles versus T-cell phenotyping.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem presents a 58-year-old woman on ipilimumab/nivolumab with aseptic meningitis (lymphocytic CSF, negative Gram stain/cytology). The question asks which CSF finding most strongly supports checkpoint inhibitor-induced meningitis over infectious/neoplastic causes. Key issue: The keyed answer (D: CD4+/CD8+ ratio >4:1 with activated phenotype) lacks robust published evidence as a specific diagnostic marker for checkpoint inhibitor meningitis. While checkpoint inhibitors enhance T-cell activation, a CD4+/CD8+ ratio >4:1 is not established as pathognomonic and could occur in various inflammatory conditions. Option C (markedly elevated IL-17) is equally plausible given that IL-17 is implicated in immune-related adverse events from checkpoint inhibitors and Th17 responses. The stem does not provide sufficient discriminating information to definitively favor D over C based on established literature. Both represent immunologic activation patterns that could theoretically support checkpoint inhibitor toxicity, but neither is validated as a gold-standard diagnostic marker. The item assumes knowledge of a specific biomarker profile that is not widely established in standard references. Minimal fix: Revise the question to ask about general immunologic patterns rather than specific ratios, or provide stem clues that better discriminate between inflammatory cytokine profiles versus T-cell phenotyping.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-003", "question": "A 6-month-old infant presents with progressive hypotonia, poor feeding, and developmental regression over 2 weeks. Parents report a recent upper respiratory infection. Examination reveals absent deep tendon reflexes, tongue fasciculations, and paradoxical breathing. EMG shows fibrillation potentials and reduced motor unit recruitment. Genetic testing for SMN1 deletions is negative. CSF protein is markedly elevated at 280 mg/dL. Which of the following is the most likely diagnosis?", "options": ["Infantile-onset Pompe disease", "Acute motor axonal neuropathy variant of Guillain-Barré syndrome", "Spinal muscular atrophy type 1 with atypical genetics", "Infantile botulism", "Cytomegalovirus-associated polyradiculopathy"], "answer": "B", "answer_index": 1, "explanation": "The combination of acute/subacute onset following infection, areflexia, tongue fasciculations (cranial nerve involvement), paradoxical breathing, EMG showing denervation, and markedly elevated CSF protein with albuminocytologic dissociation strongly suggests acute motor axonal neuropathy (AMAN), a GBS variant. SMA type 1 would have positive SMN1 testing in >95% of cases and insidious onset. Infantile botulism shows decremental response on repetitive stimulation and normal CSF. Pompe disease shows myopathic EMG changes. CMV polyradiculopathy typically occurs in immunocompromised patients.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem provides discriminating clues: (1) acute/subacute progression over 2 weeks following URI, (2) areflexia, (3) tongue fasciculations indicating cranial nerve involvement, (4) paradoxical breathing from respiratory muscle weakness, (5) EMG with fibrillation potentials and reduced motor unit recruitment consistent with denervation, (6) markedly elevated CSF protein (280 mg/dL) suggesting albuminocytologic dissociation, and (7) negative SMN1 testing excluding typical SMA. These findings collectively point to acute motor axonal neuropathy (AMAN), a GBS variant. Option A (Pompe) would show myopathic rather than neuropathic EMG changes. Option C is excluded by negative SMN1 testing and the acute time course. Option D (botulism) typically shows decremental response on repetitive nerve stimulation, not fibrillation potentials, and has normal CSF protein. Option E (CMV polyradiculopathy) occurs in immunocompromised hosts, not mentioned here. The keyed answer B is uniquely defensible based on the constellation of post-infectious acute neuropathy with cranial nerve involvement, denervation pattern on EMG, and elevated CSF protein. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem provides discriminating clues: (1) acute/subacute progression over 2 weeks following URI, (2) areflexia, (3) tongue fasciculations indicating cranial nerve involvement, (4) paradoxical breathing from respiratory muscle weakness, (5) EMG with fibrillation potentials and reduced motor unit recruitment consistent with denervation, (6) markedly elevated CSF protein (280 mg/dL) suggesting albuminocytologic dissociation, and (7) negative SMN1 testing excluding typical SMA. These findings collectively point to acute motor axonal neuropathy (AMAN), a GBS variant. Option A (Pompe) would show myopathic rather than neuropathic EMG changes. Option C is excluded by negative SMN1 testing and the acute time course. Option D (botulism) typically shows decremental response on repetitive nerve stimulation, not fibrillation potentials, and has normal CSF protein. Option E (CMV polyradiculopathy) occurs in immunocompromised hosts, not mentioned here. The keyed answer B is uniquely defensible based on the constellation of post-infectious acute neuropathy with cranial nerve involvement, denervation pattern on EMG, and elevated CSF protein. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-004", "question": "A 45-year-old man with acute myeloid leukemia undergoes allogeneic hematopoietic stem cell transplantation. On day +14, he develops fever, hypoxemia, and diffuse pulmonary infiltrates. Bronchoalveolar lavage shows hemorrhagic return with progressively bloodier aliquots. DAD is seen on transbronchial biopsy. Galactomannan, beta-D-glucan, and respiratory viral panel are negative. He is on tacrolimus with therapeutic levels. Which of the following findings would most strongly support a diagnosis of diffuse alveolar hemorrhage due to transplant-associated thrombotic microangiopathy rather than idiopathic pneumonia syndrome?", "options": ["Elevated serum lactate dehydrogenase with schistocytes on peripheral smear", "Presence of hemosiderin-laden macrophages in BAL fluid", "Concurrent acute kidney injury with proteinuria", "Elevated plasma-free hemoglobin with decreased haptoglobin", "Refractory thrombocytopenia despite platelet transfusions"], "answer": "E", "answer_index": 4, "explanation": "Transplant-associated thrombotic microangiopathy (TA-TMA) characteristically shows refractory thrombocytopenia that fails to increment appropriately with platelet transfusions due to ongoing platelet consumption in microthrombi. While elevated LDH, schistocytes, and decreased haptoglobin occur in both TA-TMA and other hemolytic processes, and AKI can occur in multiple post-transplant complications, the specific finding of platelet refractoriness distinguishes TA-TMA. Hemosiderin-laden macrophages simply confirm alveolar hemorrhage without indicating etiology. Idiopathic pneumonia syndrome does not cause platelet refractoriness.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - Option A is the best answer, not E. The stem asks which finding would \\\"most strongly support\\\" TA-TMA over idiopathic pneumonia syndrome (IPS) in a patient with diffuse alveolar hemorrhage (DAH). Key discriminating findings: post-HSCT day +14, DAH with DAD on biopsy, on tacrolimus (calcineurin inhibitor - TA-TMA risk factor). TA-TMA is a systemic thrombotic microangiopathy (TMA) requiring evidence of microangiopathic hemolytic anemia (MAHA) plus organ injury. Option A (elevated LDH + schistocytes) directly demonstrates MAHA, the hallmark laboratory finding distinguishing TA-TMA from IPS. Option E (refractory thrombocytopenia) is nonspecific - thrombocytopenia occurs in both TA-TMA and IPS, and platelet refractoriness can result from multiple post-transplant causes (alloimmunization, sepsis, medications). The rationale incorrectly claims schistocytes occur in \\\"other hemolytic processes\\\" without recognizing that schistocytes specifically indicate microangiopathic hemolysis, which is pathognomonic for TMA and does NOT occur in IPS. Options C and D support TMA but are less specific than the combination in A. Option B confirms hemorrhage but not etiology. Medical accuracy issue: The keyed answer conflates a supportive finding (thrombocytopenia) with the diagnostic hallmark (MAHA). Minimal fix: Change key to A.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - Option A is the best answer, not E. The stem asks which finding would \"most strongly support\" TA-TMA over idiopathic pneumonia syndrome (IPS) in a patient with diffuse alveolar hemorrhage (DAH). Key discriminating findings: post-HSCT day +14, DAH with DAD on biopsy, on tacrolimus (calcineurin inhibitor - TA-TMA risk factor). TA-TMA is a systemic thrombotic microangiopathy (TMA) requiring evidence of microangiopathic hemolytic anemia (MAHA) plus organ injury. Option A (elevated LDH + schistocytes) directly demonstrates MAHA, the hallmark laboratory finding distinguishing TA-TMA from IPS. Option E (refractory thrombocytopenia) is nonspecific - thrombocytopenia occurs in both TA-TMA and IPS, and platelet refractoriness can result from multiple post-transplant causes (alloimmunization, sepsis, medications). The rationale incorrectly claims schistocytes occur in \"other hemolytic processes\" without recognizing that schistocytes specifically indicate microangiopathic hemolysis, which is pathognomonic for TMA and does NOT occur in IPS. Options C and D support TMA but are less specific than the combination in A. Option B confirms hemorrhage but not etiology. Medical accuracy issue: The keyed answer conflates a supportive finding (thrombocytopenia) with the diagnostic hallmark (MAHA). Minimal fix: Change key to A.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-005", "question": "A 3-year-old girl presents with acute onset right-sided weakness and slurred speech. CT head is negative for hemorrhage. MRI reveals acute left middle cerebral artery territory infarction. Echocardiogram shows no structural abnormalities or vegetations. Hypercoagulability workup including protein C, protein S, antithrombin III, factor V Leiden, and prothrombin gene mutation are normal. Hemoglobin electrophoresis is normal. She had chickenpox 6 weeks ago. Cerebral angiography shows focal stenosis of the left distal internal carotid artery with a \"beaded\" appearance. Which of the following is the most appropriate long-term management?", "options": ["Lifelong warfarin anticoagulation", "Aspirin therapy for 2 years with serial vascular imaging", "Immediate surgical bypass of the stenotic segment", "High-dose intravenous immunoglobulin monthly", "Indefinite dual antiplatelet therapy with aspirin and clopidogrel"], "answer": "B", "answer_index": 1, "explanation": "This presentation is classic for post-varicella arteriopathy (transient cerebral arteriopathy), which causes focal stenosis of large intracranial arteries following VZV infection. The condition is typically monophasic and self-limiting, with arterial changes stabilizing or improving over 6-24 months. Current guidelines recommend aspirin therapy for approximately 2 years with serial vascular imaging to monitor for progression or resolution. Anticoagulation is not superior to antiplatelet therapy and carries higher bleeding risk. Surgical bypass is not indicated for this typically self-resolving condition. IVIG has no established role in post-varicella arteriopathy.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 3-year-old with acute stroke 6 weeks post-varicella, negative hypercoagulability workup, and angiographic findings of focal stenosis with \\\"beaded\\\" appearance—classic for post-varicella arteriopathy (transient cerebral arteriopathy). Key discriminating findings: (1) temporal relationship to chickenpox, (2) focal large-vessel stenosis on angiography, (3) exclusion of cardiac emboli and hypercoagulable states. Post-varicella arteriopathy is typically monophasic and self-limiting, with arterial changes stabilizing/improving over 6-24 months. Option B (aspirin for 2 years with serial imaging) aligns with current pediatric stroke guidelines for this condition. Option A (lifelong warfarin) is excessive for a self-limiting arteriopathy and carries higher bleeding risk without proven superiority. Option C (surgical bypass) is inappropriate for a typically reversible condition. Option D (monthly IVIG) lacks evidence for post-varicella arteriopathy. Option E (dual antiplatelet therapy indefinitely) is excessive duration and intensity for this transient condition. The item is logically valid with a unique best answer matching the key. Medical accuracy is high, reflecting current pediatric stroke management standards. Minimal fix: None needed; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 3-year-old with acute stroke 6 weeks post-varicella, negative hypercoagulability workup, and angiographic findings of focal stenosis with \"beaded\" appearance—classic for post-varicella arteriopathy (transient cerebral arteriopathy). Key discriminating findings: (1) temporal relationship to chickenpox, (2) focal large-vessel stenosis on angiography, (3) exclusion of cardiac emboli and hypercoagulable states. Post-varicella arteriopathy is typically monophasic and self-limiting, with arterial changes stabilizing/improving over 6-24 months. Option B (aspirin for 2 years with serial imaging) aligns with current pediatric stroke guidelines for this condition. Option A (lifelong warfarin) is excessive for a self-limiting arteriopathy and carries higher bleeding risk without proven superiority. Option C (surgical bypass) is inappropriate for a typically reversible condition. Option D (monthly IVIG) lacks evidence for post-varicella arteriopathy. Option E (dual antiplatelet therapy indefinitely) is excessive duration and intensity for this transient condition. The item is logically valid with a unique best answer matching the key. Medical accuracy is high, reflecting current pediatric stroke management standards. Minimal fix: None needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-006", "question": "A 62-year-old man with small cell lung cancer develops progressive proximal weakness over 3 months. He has difficulty rising from chairs and climbing stairs. Examination reveals proximal muscle weakness (3/5), preserved reflexes, and no sensory deficits. CK is 4,200 U/L. EMG shows myopathic changes with fibrillation potentials. Muscle biopsy reveals necrotic and regenerating fibers with minimal inflammatory infiltrate. Testing for anti-Jo-1, anti-Mi-2, anti-SRP, and anti-MDA5 antibodies is negative. Which antibody is most likely to be positive in this patient?", "options": ["Anti-HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase)", "Anti-TIF1-gamma (transcription intermediary factor 1-gamma)", "Anti-NXP-2 (nuclear matrix protein 2)", "Anti-SAE (small ubiquitin-like modifier activating enzyme)", "Anti-HMGCR antibodies with concurrent anti-SRP positivity"], "answer": "B", "answer_index": 1, "explanation": "Anti-TIF1-gamma antibodies are strongly associated with malignancy-associated dermatomyositis/inflammatory myopathy, particularly in adults over 40 with underlying cancer. Small cell lung cancer is a known associated malignancy. The biopsy showing necrotizing features with minimal inflammation is consistent with immune-mediated necrotizing myopathy, which can occur with TIF1-gamma positivity in cancer-associated cases. Anti-HMGCR is associated with statin exposure and necrotizing myopathy but not specifically with malignancy. Anti-NXP-2 is associated with calcinosis and juvenile dermatomyositis. Anti-SAE is associated with dermatomyositis with systemic features but lower malignancy risk.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 62-year-old man with small cell lung cancer and proximal weakness, elevated CK (4,200), myopathic EMG with fibrillations, and muscle biopsy showing necrotic/regenerating fibers with minimal inflammation—classic for immune-mediated necrotizing myopathy (IMNM). The stem explicitly states anti-SRP is negative, leaving anti-HMGCR (option A) as the primary remaining IMNM antibody. Anti-HMGCR myopathy presents with proximal weakness, high CK, necrotizing biopsy with minimal inflammation, and fibrillations—matching this case perfectly. While statin exposure is common, anti-HMGCR can occur without statin use. The keyed answer (B, anti-TIF1-gamma) is associated with cancer-associated dermatomyositis, but the clinical picture lacks dermatomyositis features (no rash mentioned), and the biopsy description (necrotizing with minimal inflammation) is atypical for classic dermatomyositis, which usually shows perifascicular atrophy and perivascular inflammation. Both A and B are defensible: A fits the necrotizing myopathy phenotype precisely; B fits the malignancy association but requires assuming dermatomyositis without typical features. Main logical issue: The stem does not specify presence/absence of rash or statin use—critical discriminators. Minimal fix: Add 'no rash' and 'no statin use' to make anti-TIF1-gamma clearly best, or add 'heliotrope rash' to eliminate anti-HMGCR.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 62-year-old man with small cell lung cancer and proximal weakness, elevated CK (4,200), myopathic EMG with fibrillations, and muscle biopsy showing necrotic/regenerating fibers with minimal inflammation—classic for immune-mediated necrotizing myopathy (IMNM). The stem explicitly states anti-SRP is negative, leaving anti-HMGCR (option A) as the primary remaining IMNM antibody. Anti-HMGCR myopathy presents with proximal weakness, high CK, necrotizing biopsy with minimal inflammation, and fibrillations—matching this case perfectly. While statin exposure is common, anti-HMGCR can occur without statin use. The keyed answer (B, anti-TIF1-gamma) is associated with cancer-associated dermatomyositis, but the clinical picture lacks dermatomyositis features (no rash mentioned), and the biopsy description (necrotizing with minimal inflammation) is atypical for classic dermatomyositis, which usually shows perifascicular atrophy and perivascular inflammation. Both A and B are defensible: A fits the necrotizing myopathy phenotype precisely; B fits the malignancy association but requires assuming dermatomyositis without typical features. Main logical issue: The stem does not specify presence/absence of rash or statin use—critical discriminators. Minimal fix: Add 'no rash' and 'no statin use' to make anti-TIF1-gamma clearly best, or add 'heliotrope rash' to eliminate anti-HMGCR.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-007", "question": "A 28-year-old woman at 32 weeks gestation presents with severe headache, visual changes, and right upper quadrant pain. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 62,000/μL, AST 342 U/L, ALT 298 U/L, LDH 890 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. Urinalysis shows 3+ protein. She receives magnesium sulfate and labetalol. Despite delivery 6 hours later, her platelet count drops to 28,000/μL and creatinine rises to 3.2 mg/dL over the next 48 hours. ADAMTS13 activity returns at 68%. Which of the following is the most appropriate next step in management?", "options": ["Initiate therapeutic plasma exchange", "Administer eculizumab", "Begin rituximab infusion", "Transfuse platelets to maintain count above 50,000/μL", "Continue supportive care with expectant management"], "answer": "B", "answer_index": 1, "explanation": "This patient has pregnancy-associated atypical hemolytic uremic syndrome (aHUS), evidenced by persistent/worsening microangiopathic hemolytic anemia and renal failure after delivery with ADAMTS13 activity >10% (ruling out TTP). Complement-mediated aHUS can be triggered by pregnancy and does not resolve with delivery alone. Eculizumab, a C5 complement inhibitor, is the treatment of choice for aHUS. Plasma exchange is first-line for TTP (ADAMTS13 <10%) but less effective in aHUS. Rituximab targets B cells and is used for autoimmune TTP. Platelet transfusion is relatively contraindicated in TMA. Expectant management risks progressive renal failure.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes severe preeclampsia/ECLAMPSIA syndrome with HELLP features (hemolysis, elevated liver enzymes, low platelets) that worsens postpartum. Key findings: 32 weeks gestation, severe hypertension (178/112), thrombocytopenia (62k→28k), elevated transaminases, AKI (Cr 1.8→3.2), schistocytes, proteinuria, symptoms persist/worsen 48 hours post-delivery. ADAMTS13 68% excludes TTP. The critical issue: the stem does not provide sufficient evidence to definitively distinguish between postpartum HELLP syndrome (which can persist/worsen after delivery) versus pregnancy-associated aHUS. Both present identically with microangiopathic hemolytic anemia, thrombocytopenia, and AKI postpartum. ADAMTS13 >10% excludes TTP but does NOT establish aHUS diagnosis—it merely rules out one differential. Without complement studies (C3/C4, genetic testing, anti-CFH antibodies) or explicit failure of standard postpartum HELLP management, both diagnoses remain plausible. If HELLP: supportive care (E) is standard. If aHUS: eculizumab (B) is indicated. The item assumes aHUS without providing discriminating data. Minimal fix: Add complement studies showing dysregulation (low C3, positive genetic mutation) or explicitly state HELLP management failed, making aHUS the remaining diagnosis requiring eculizumab.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes severe preeclampsia/ECLAMPSIA syndrome with HELLP features (hemolysis, elevated liver enzymes, low platelets) that worsens postpartum. Key findings: 32 weeks gestation, severe hypertension (178/112), thrombocytopenia (62k→28k), elevated transaminases, AKI (Cr 1.8→3.2), schistocytes, proteinuria, symptoms persist/worsen 48 hours post-delivery. ADAMTS13 68% excludes TTP. The critical issue: the stem does not provide sufficient evidence to definitively distinguish between postpartum HELLP syndrome (which can persist/worsen after delivery) versus pregnancy-associated aHUS. Both present identically with microangiopathic hemolytic anemia, thrombocytopenia, and AKI postpartum. ADAMTS13 >10% excludes TTP but does NOT establish aHUS diagnosis—it merely rules out one differential. Without complement studies (C3/C4, genetic testing, anti-CFH antibodies) or explicit failure of standard postpartum HELLP management, both diagnoses remain plausible. If HELLP: supportive care (E) is standard. If aHUS: eculizumab (B) is indicated. The item assumes aHUS without providing discriminating data. Minimal fix: Add complement studies showing dysregulation (low C3, positive genetic mutation) or explicitly state HELLP management failed, making aHUS the remaining diagnosis requiring eculizumab.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-008", "question": "A 14-year-old boy with no significant medical history presents after a witnessed generalized tonic-clonic seizure lasting 2 minutes with spontaneous termination. He reports a 3-month history of early morning myoclonic jerks causing him to drop objects, which he attributed to clumsiness. EEG shows 4-6 Hz generalized polyspike-and-wave discharges with photosensitivity. MRI brain is normal. His father had similar episodes as a teenager that resolved. Which of the following medications should be specifically avoided in this patient?", "options": ["Levetiracetam", "Valproic acid", "Lamotrigine", "Carbamazepine", "Topiramate"], "answer": "D", "answer_index": 3, "explanation": "This patient has juvenile myoclonic epilepsy (JME), characterized by myoclonic jerks (especially morning), generalized tonic-clonic seizures, photosensitivity, and generalized polyspike-and-wave on EEG. Carbamazepine and other sodium channel blockers (phenytoin, oxcarbazepine) can paradoxically worsen myoclonic and absence seizures in genetic generalized epilepsies like JME by enhancing thalamocortical synchronization. Valproic acid is highly effective but avoided in women of childbearing potential due to teratogenicity. Levetiracetam and lamotrigine are appropriate alternatives. Topiramate has broad-spectrum efficacy including in JME.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 14-year-old boy with classic juvenile myoclonic epilepsy (JME): early morning myoclonic jerks (dropping objects), generalized tonic-clonic seizure, 4-6 Hz generalized polyspike-and-wave discharges with photosensitivity on EEG, normal MRI, and positive family history. The question asks which medication should be specifically avoided. Key discriminating findings: myoclonic jerks, generalized epilepsy pattern, photosensitivity. Carbamazepine (D) is the correct answer because sodium channel blockers paradoxically worsen myoclonic and absence seizures in genetic generalized epilepsies by enhancing thalamocortical synchronization—this is well-established and board-relevant. Alternative assessment: (A) Levetiracetam is first-line for JME; (B) Valproic acid is highly effective for JME (teratogenicity concern applies to females, not this male patient); (C) Lamotrigine is appropriate for JME; (E) Topiramate has broad-spectrum efficacy including JME. All alternatives are acceptable or preferred treatments. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent—reflects current standard practice and USMLE-level teaching. No fix needed; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 14-year-old boy with classic juvenile myoclonic epilepsy (JME): early morning myoclonic jerks (dropping objects), generalized tonic-clonic seizure, 4-6 Hz generalized polyspike-and-wave discharges with photosensitivity on EEG, normal MRI, and positive family history. The question asks which medication should be specifically avoided. Key discriminating findings: myoclonic jerks, generalized epilepsy pattern, photosensitivity. Carbamazepine (D) is the correct answer because sodium channel blockers paradoxically worsen myoclonic and absence seizures in genetic generalized epilepsies by enhancing thalamocortical synchronization—this is well-established and board-relevant. Alternative assessment: (A) Levetiracetam is first-line for JME; (B) Valproic acid is highly effective for JME (teratogenicity concern applies to females, not this male patient); (C) Lamotrigine is appropriate for JME; (E) Topiramate has broad-spectrum efficacy including JME. All alternatives are acceptable or preferred treatments. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent—reflects current standard practice and USMLE-level teaching. No fix needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-009", "question": "A 55-year-old man is admitted to the ICU with septic shock secondary to necrotizing pancreatitis. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, his MAP remains 58 mmHg. Vasopressin 0.04 units/min is added. Central venous oxygen saturation is 58%, lactate is 6.2 mmol/L, and cardiac index by thermodilution is 2.0 L/min/m². Echocardiogram shows hyperdynamic left ventricle with LVEF 70% and small, underfilled chambers. Which of the following is the most appropriate next intervention?", "options": ["Add dobutamine for inotropic support", "Administer additional crystalloid bolus", "Initiate phenylephrine infusion", "Add epinephrine as third vasopressor", "Begin hydrocortisone 50 mg IV every 6 hours"], "answer": "B", "answer_index": 1, "explanation": "Despite initial resuscitation, the echocardiographic findings of hyperdynamic LV with small, underfilled chambers indicate persistent hypovolemia. The low ScvO2 (58%) and elevated lactate suggest inadequate oxygen delivery. In the setting of distributive shock with evidence of preload deficiency, additional volume resuscitation is indicated before adding further vasopressors. Dobutamine would be inappropriate given the already hyperdynamic state. Phenylephrine causes pure vasoconstriction without inotropy and may worsen cardiac output. Epinephrine could be considered after optimizing preload. Hydrocortisone is indicated for refractory shock but addressing hypovolemia takes priority.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes septic shock with norepinephrine 0.5 mcg/kg/min and vasopressin already on board, MAP 58 mmHg, ScvO2 58%, lactate 6.2, cardiac index 2.0, and echo showing hyperdynamic LV with small underfilled chambers. Key discriminating findings: (1) already on two vasopressors with inadequate MAP, (2) low ScvO2 and elevated lactate indicating tissue hypoperfusion, (3) echo suggests hypovolemia BUT patient has already received \\\"adequate fluid resuscitation\\\" per stem. This creates internal tension: if resuscitation was truly adequate, chambers shouldn't be underfilled; if inadequate, the stem contradicts itself. The keyed answer (B, more fluids) assumes \\\"adequate\\\" was insufficient, but option E (hydrocortisone for vasopressor-refractory shock on 2+ agents) is equally defensible per Surviving Sepsis guidelines for relative adrenal insufficiency in refractory shock. Option D (epinephrine) is also reasonable as third-line agent. The stem's assertion of \\\"adequate\\\" resuscitation yet persistent underfilling creates ambiguity about whether volume or vasopressor-refractory physiology is primary. Medical accuracy: mostly sound but the internal contradiction regarding adequacy of resuscitation undermines clarity. Minimal fix: Remove \\\"adequate fluid resuscitation\\\" or specify exact volume given and CVP/dynamic parameters to unambiguously establish ongoing hypovolemia versus refractory shock requiring steroids.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes septic shock with norepinephrine 0.5 mcg/kg/min and vasopressin already on board, MAP 58 mmHg, ScvO2 58%, lactate 6.2, cardiac index 2.0, and echo showing hyperdynamic LV with small underfilled chambers. Key discriminating findings: (1) already on two vasopressors with inadequate MAP, (2) low ScvO2 and elevated lactate indicating tissue hypoperfusion, (3) echo suggests hypovolemia BUT patient has already received \"adequate fluid resuscitation\" per stem. This creates internal tension: if resuscitation was truly adequate, chambers shouldn't be underfilled; if inadequate, the stem contradicts itself. The keyed answer (B, more fluids) assumes \"adequate\" was insufficient, but option E (hydrocortisone for vasopressor-refractory shock on 2+ agents) is equally defensible per Surviving Sepsis guidelines for relative adrenal insufficiency in refractory shock. Option D (epinephrine) is also reasonable as third-line agent. The stem's assertion of \"adequate\" resuscitation yet persistent underfilling creates ambiguity about whether volume or vasopressor-refractory physiology is primary. Medical accuracy: mostly sound but the internal contradiction regarding adequacy of resuscitation undermines clarity. Minimal fix: Remove \"adequate fluid resuscitation\" or specify exact volume given and CVP/dynamic parameters to unambiguously establish ongoing hypovolemia versus refractory shock requiring steroids.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-010", "question": "A 7-year-old boy presents with 2 weeks of progressive gait instability and tremor. Examination reveals opsoclonus (chaotic, multidirectional saccadic eye movements), myoclonus, and truncal ataxia. MRI brain and spine are normal. CSF shows mild lymphocytic pleocytosis. CT chest/abdomen/pelvis reveals a paraspinal mass. Urine catecholamines are elevated. Tumor resection is planned. Which of the following additional findings would indicate the WORST long-term neurodevelopmental prognosis despite tumor treatment?", "options": ["Presence of anti-Hu antibodies in serum", "CSF oligoclonal bands with elevated IgG index", "Age less than 3 years at symptom onset", "Tumor histology showing neuroblastoma with MYCN amplification", "Delayed initiation of immunotherapy beyond 4 weeks from diagnosis"], "answer": "C", "answer_index": 2, "explanation": "Opsoclonus-myoclonus-ataxia syndrome (OMS) associated with neuroblastoma has variable neurodevelopmental outcomes. Younger age at onset (particularly <3 years) is paradoxically associated with worse long-term cognitive and behavioral outcomes, likely due to the impact of neuroinflammation on the developing brain during critical periods. While MYCN amplification indicates aggressive tumor biology, it does not correlate with neurological outcomes. Anti-Hu antibodies are rare in pediatric OMS. CSF inflammatory markers and treatment delays affect outcomes but age remains the strongest predictor of neurodevelopmental sequelae.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes classic opsoclonus-myoclonus-ataxia syndrome (OMS) in a child with neuroblastoma (paraspinal mass, elevated urine catecholamines). The question asks for the worst prognostic factor for long-term neurodevelopmental outcomes despite tumor treatment. Key stem clues: 7-year-old with OMS, neuroblastoma confirmed. Choice C (age <3 years at onset) is the keyed answer. The patient is 7 years old, so this choice requires understanding that the question asks which finding \\\"would indicate\\\" worst prognosis if present—a hypothetical comparison. This is a standard exam format testing knowledge of prognostic factors. Age <3 years at OMS onset is well-established as the strongest predictor of poor neurodevelopmental outcomes due to neuroinflammation during critical brain development periods. Choice A (anti-Hu) is rare in pediatric OMS and more associated with adult paraneoplastic syndromes. Choice B (CSF markers) indicates inflammation but is not the strongest prognostic factor. Choice D (MYCN amplification) predicts tumor aggressiveness but not neurological outcomes in OMS. Choice E (treatment delay) affects outcomes but age remains the dominant predictor. The item is medically accurate and logically valid with a unique best answer matching the key. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes classic opsoclonus-myoclonus-ataxia syndrome (OMS) in a child with neuroblastoma (paraspinal mass, elevated urine catecholamines). The question asks for the worst prognostic factor for long-term neurodevelopmental outcomes despite tumor treatment. Key stem clues: 7-year-old with OMS, neuroblastoma confirmed. Choice C (age <3 years at onset) is the keyed answer. The patient is 7 years old, so this choice requires understanding that the question asks which finding \"would indicate\" worst prognosis if present—a hypothetical comparison. This is a standard exam format testing knowledge of prognostic factors. Age <3 years at OMS onset is well-established as the strongest predictor of poor neurodevelopmental outcomes due to neuroinflammation during critical brain development periods. Choice A (anti-Hu) is rare in pediatric OMS and more associated with adult paraneoplastic syndromes. Choice B (CSF markers) indicates inflammation but is not the strongest prognostic factor. Choice D (MYCN amplification) predicts tumor aggressiveness but not neurological outcomes in OMS. Choice E (treatment delay) affects outcomes but age remains the dominant predictor. The item is medically accurate and logically valid with a unique best answer matching the key. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]